Donanemab is an investigational antibody therapy that targets a modified form of deposited amyloid-β peptide called N3pG.
All articles by Brian Park, PharmD
This case report described the first instance of a patient with Crohn disease and relapsing polychondritis who presented with pachymeningitis.
This first-in-class, serotonin (5-HT) 1F receptor agonist is believed to exert its therapeutic effects both centrally and peripherally.
Mylan Pharmaceuticals announced the voluntary recall of one lot of alprazolam 0.5mg tablets to the consumer/user level due to the potential presence of a foreign substance.
Latest News Your top articles for FridayFor More Personalized News
Haymarket Medical NetworkTop Picks
Continuing Medical Education (CME/CE) Courses